Regeneron Pharmaceuticals

This study tests an experimental drug called ALN-SNCA in 46 people with early Parkinson's disease. The drug is given as a single injection into the spinal fluid to see if it is safe and can lower a harmful protein called alpha-synuclein. The goal is to find a treatment that slows…

This study tests a new experimental drug, REGN7945, combined with another experimental drug, linvoseltamab, in people whose multiple myeloma has returned or not responded to at least three prior treatments. The goal is to see if the combination is safer and works better than linv…

This study tests a new drug, mibavademab, in people with generalized lipodystrophy, a rare condition where the body lacks fat tissue. The goal is to see if the drug can improve blood sugar and fat levels. About 28 children and adults will take part in this Phase 3 trial, which co…

This study tests two experimental drugs, ubamatamab and REGN7075, in people with advanced or metastatic non-small cell lung cancer who have already tried standard treatments. The goal is to see if the combination can shrink tumors and control the disease. About 300 participants w…

This study tests two experimental drugs, pozelimab and cemdisiran, to see if they can slow the growth of blind spots (geographic atrophy) in people with advanced dry age-related macular degeneration (AMD). About 975 participants will receive either the drugs or a placebo by injec…

This phase 3 study compares an experimental drug, linvoseltamab, to a standard three-drug combination (EPd) in people with multiple myeloma that has returned after 1-4 prior treatments. About 410 participants will be randomly assigned to receive either linvoseltamab or EPd. The m…

This study tests an experimental drug, REGN5668, alone or with other immune-boosting medicines in people with ovarian, fallopian tube, peritoneal, or endometrial cancers. The goal is to find the safest dose and see if the combination shrinks tumors. About 612 adults whose cancer …

This early-stage study tests an experimental drug called pozelimab, given as an injection into the eye, for people with geographic atrophy (GA), a condition that damages the retina and causes vision loss. The main goal is to check if the drug is safe and tolerable. About 54 parti…

This early-phase study tests an experimental drug, linvoseltamab, combined with dupilumab in 6 adults with severe food allergies (like peanut or milk) that can cause life-threatening reactions. The goal is to see if the combo is safe and how it affects IgE antibodies, which drive…

This early-stage study tests an experimental drug, REGN10597, alone or with another drug (cemiplimab) in people with advanced solid tumors like melanoma and kidney cancer. The main goals are to check safety, find the right dose, and see if the drugs shrink tumors. About 240 parti…

This study tests whether injecting the drug cemiplimab directly into early-stage skin cancer tumors can work as well as surgery to remove them. About 369 adults with a type of skin cancer called cutaneous squamous cell carcinoma will be randomly assigned to get either the injecti…

This study tests two experimental drugs, REGN7508 and REGN9933, to prevent blood clots in people with atrial fibrillation (an irregular heartbeat). About 1,200 participants will receive one of the new drugs or the standard blood thinner apixaban. The main goal is to see if the ne…

This study tests a new drug, REGN17372, combined with another drug, linvoseltamab, in people whose multiple myeloma has returned or stopped responding to treatment. The goal is to find a safe dose and see if the combination shrinks tumors better than linvoseltamab alone. About 15…

This study tests a new gene therapy called REGV131-LNP1265 for people with severe or moderately severe hemophilia B. The therapy uses CRISPR to insert a working gene so the body can produce its own clotting factor, potentially reducing or eliminating the need for regular factor r…

This study tests a new drug, odronextamab, combined with lenalidomide in people whose follicular or marginal zone lymphoma has returned or stopped responding to treatment. The trial compares this new combination to the current standard treatment (rituximab plus lenalidomide). Abo…

This expanded access program provides REGN4461 to patients with lipodystrophy or monogenic obesity caused by deficient leptin signaling. The goal is to offer treatment to those who have no other options. Participants receive the drug under close medical supervision.

This early-stage study tests experimental bispecific antibody drugs in people with lupus nephritis, a serious kidney complication of lupus. The main goal is to see if the drugs are safe and tolerable over the long term. About 90 participants with hard-to-treat or relapsed disease…

This study tests two experimental drugs (ALN-ANG3 and evinacumab) in about 270 adults with diabetic kidney disease. The goal is to see if they safely reduce protein in the urine and help preserve kidney function. Participants must have type 2 diabetes and moderate to severe kidne…

This early-stage study tests a new drug (REGN5837) combined with another drug (odronextamab) in about 107 people whose aggressive B-cell lymphoma has not responded to at least two prior treatments. The first part finds a safe dose; the second part checks how well the combination …

This study tests a new drug, linvoseltamab, in about 387 people whose multiple myeloma has returned or stopped responding to other treatments. The main goals are to check the drug's safety and find the best dose, while also seeing if it can shrink the cancer. Participants must be…

This study tests an experimental drug called REGN13335 in 99 adults with pulmonary arterial hypertension (PAH), a condition where high blood pressure in the lungs makes the heart work harder. Participants will receive either the drug or a placebo alongside their usual PAH medicat…

This study tests a new drug, linvoseltamab, given alone or with another drug called carfilzomib, against standard treatments for people with multiple myeloma that has come back or stopped responding to therapy. About 915 participants who have had 1 to 3 prior treatments will be e…

This study tests an experimental drug called ALN-CFB in people with paroxysmal nocturnal hemoglobinuria (PNH) who still have low red blood cells despite standard treatment. The goal is to see if adding ALN-CFB is safe and can improve anemia. About 24 participants will receive eit…

This study tests an experimental drug, linvoseltamab, in people with newly diagnosed multiple myeloma, a type of blood cancer. The drug aims to shrink tumors and control the disease. About 149 participants will join, and the study will check safety, side effects, and how well the…

This study tests an investigational drug called linvoseltamab in people with two precancerous conditions—high-risk MGUS and non-high-risk smoldering multiple myeloma—that raise the risk of developing multiple myeloma. The goal is to see if the drug can eliminate abnormal plasma c…

This study is for people with paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disorder. It tests the long-term safety and effectiveness of two experimental drugs, pozelimab and cemdisiran, taken together. About 202 participants will receive the combination therapy to see …

This study tests an experimental drug called ubamatamab, alone or with other cancer drugs, in people with advanced ovarian cancer that has stopped responding to platinum-based chemotherapy. The goal is to see how safe and effective these combinations are. About 220 participants w…

This study tests a new drug called olatorepatide in 120 adults who are overweight or obese but do not have diabetes. The drug aims to help with weight loss by targeting hormones that control appetite. Researchers will check how safe the drug is, how the body processes it, and how…

This study tests an experimental drug called ALN-CIDEB in adults with fatty liver disease (MASLD or MASH). The main goal is to check safety and side effects, and also see if it reduces liver fat. About 132 participants will receive either the drug or a placebo.

This study tests an experimental drug called REGN7999 in people with a type of beta-thalassemia that doesn't require regular blood transfusions. The goal is to see if the drug safely reduces the extra iron that builds up in the body, which can damage organs. About 95 participants…

This study tests a new two-drug combination (fianlimab and cemiplimab) against an already approved combination (relatlimab and nivolumab, sold as Opdualag) in people with advanced melanoma that cannot be removed by surgery or has spread. About 560 adults who have not had prior tr…

This study tests an experimental drug called ALN-PNP for metabolic dysfunction-associated steatotic liver disease (MASLD). It is the first time this drug is being tested in humans. The study includes healthy adults and people with MASLD who have a specific gene variant. The main …

This program provides early access to ubamatamab, an experimental drug, for people with two rare and serious cancers: renal medullary carcinoma and epithelioid sarcoma. The goal is to offer a potential treatment option when no other therapies are available. Eligibility is decided…

This study tests two experimental drugs, REGN4336 and REGN5678, for men with metastatic castration-resistant prostate cancer that has worsened after prior treatments. The goal is to find safe doses and see if the combination can shrink tumors. About 228 participants will take par…

This study tests a drug called vonsetamig in people with chronic kidney disease who have very high levels of antibodies that make it nearly impossible to find a matching donor kidney. The goal is to safely lower those antibodies so they can receive a kidney transplant. About 56 a…

This study looks at 250 adults with asthma that is not well controlled by their current medium-dose inhaler. Researchers want to see if adding a drug called dupilumab to the usual inhaler works better than simply increasing the inhaler dose. The goal is to reduce severe asthma at…

This early-stage study tests an experimental drug called linvoseltamab combined with other cancer treatments for people with multiple myeloma that has come back after prior therapy. The main goal is to see if these combinations are safe and to find the right doses. About 317 part…

This study tests whether adding an experimental drug (fianlimab) to a standard immunotherapy (cemiplimab) works better than the standard drug alone for people with head and neck cancer that has come back or spread. About 120 adults whose tumors have a specific protein (PD-L1) wil…

This study tests an experimental drug called marlotamig (REGN7075) alone or with cemiplimab (with or without chemo) in people with advanced solid tumors. The goal is to find the safest dose and see if the combination can shrink tumors or slow their growth. About 933 participants …

This study tests an experimental drug called ALN-SOD in people with ALS caused by a specific gene change (SOD1 mutation). The main goal is to check safety and how well the drug is tolerated. Researchers will also measure biomarkers and drug levels in blood and spinal fluid. About…

This study tests an experimental drug called ALN-HSD for people with MASH, a liver disease caused by fat buildup that leads to scarring and possible liver failure. The drug uses gene silencing to target the root cause and reduce liver fibrosis. About 120 adults with genetic risk …

This study tests an experimental drug called odronextamab for people with aggressive B-cell non-Hodgkin lymphoma whose cancer has returned or no longer responds to treatment. About 216 participants will receive either the new drug or standard therapy to compare safety, effectiven…

This study tests two experimental drugs, pozelimab and cemdisiran, together in 35 adults with paroxysmal nocturnal hemoglobinuria (PNH) whose current C5 inhibitor therapy isn't fully controlling red blood cell destruction. The main goal is to see if the combination lowers a key b…

This study tests an experimental drug called ubamatamab, given alone or with another drug (cemiplimab), for people with ovarian, fallopian tube, peritoneal, or endometrial cancer that has come back. The main goals are to check safety, find the best dose, and see if the drugs can …

This study tests an experimental drug, linvoseltamab, in people with a rare disease called AL amyloidosis that has returned or not responded to other treatments. The goal is to find the right dose and see if the drug can reduce abnormal proteins causing organ damage. About 220 pa…

This program provides emergency access to an experimental antibody treatment (REGN-EB3) for people sick with Ebola virus disease in outbreak regions. It is for patients who are not eligible for or cannot join the main clinical trials. The goal is to control the viral infection an…

This study tests an experimental drug, dupilumab, in 20 young children (6 months and older, weighing 5 to 15 kg) with active eosinophilic esophagitis (EoE), a condition that causes throat inflammation and feeding problems. The goal is to see if the drug is safe and can reduce inf…

This study tests a drug called pozelimab in 5 children aged 1 to 5 who have CHAPLE disease, a rare inherited condition causing severe stomach and heart problems. The main goal is to see if the drug is safe and what side effects may occur. Researchers will also measure drug levels…

This study tests an experimental drug, mibavademab, in people with a rare genetic condition that prevents the body from feeling full, leading to severe obesity. The drug aims to replace the missing signal so patients can better control their appetite and weight. Only 4 participan…

This study tests an experimental drug called mibavademab in 34 women with functional hypothalamic amenorrhea (FHA), a condition where stress, low body weight, or excessive exercise stops periods. The goal is to see if the drug can restore the hormones needed for ovulation and imp…

This study is for adults with early-stage non-small cell lung cancer who are scheduled for surgery. Researchers want to see if adding a third drug to the standard immunotherapy (cemiplimab) and chemotherapy helps shrink tumors more before surgery and keeps cancer away longer. Abo…

This program gives people with certain types of lymphoma (like follicular lymphoma or diffuse large B-cell lymphoma) who have tried all other treatments access to an experimental drug called odronextamab. The goal is to provide a possible treatment option when no others are avail…

This early-phase study tests an experimental treatment called 27T51, a type of CAR T cell therapy that targets a protein (MUC16) found on certain cancer cells. It is for women with recurrent or hard-to-treat ovarian, peritoneal, or fallopian tube cancer. The study has two parts: …

This study tests a new drug called REGN5093 in people with advanced non-small cell lung cancer that has a specific change in the MET gene. The goal is to find a safe dose and see if the drug can shrink tumors. About 231 participants will take part in two phases: first to check sa…

This study tests a new drug called REGN5678, alone or with another drug (cemiplimab), in people with advanced prostate or kidney cancer that has spread. The goal is to find safe doses and see if the drugs can shrink tumors by helping the immune system attack cancer cells. About 3…

This study tests a new drug, odronextamab, for people with untreated follicular lymphoma, a type of blood cancer. In the first part, researchers check the drug's safety alone. In the second part, they compare it to standard treatments like rituximab plus chemotherapy. About 822 p…

This study tests a new gene therapy called DB-OTO for children with hearing loss caused by changes in the otoferlin gene. The treatment is injected into the inner ear to help restore hearing. Researchers will check if it is safe and how well it works in up to 30 children and infa…

This study tests a new imaging agent (89Zr-DFO-REGN5054) that may show where immune cells are active in tumors. About 50 adults with advanced solid cancers will receive the agent and a PET scan, along with the immunotherapy cemiplimab. The goal is to check safety and see if the s…

This study tests an experimental drug called REGN7508 against aspirin to prevent dangerous blood clots in adults after knee replacement surgery. About 2000 participants will receive either the new drug or aspirin. The goal is to see which works better at preventing clots and rela…

This study tests an experimental drug, REGN7508, to prevent dangerous blood clots in adults having knee replacement surgery. About 2000 participants will receive either REGN7508 or standard blood thinners (apixaban or enoxaparin). The goal is to see if the new drug works better a…

This study tests an experimental drug, REGN7508, to see if it can prevent blood clots in people with solid tumors who are receiving cancer treatment. About 860 participants will be randomly assigned to receive either the drug or a placebo. The study will track how many people dev…

This study tests two experimental drugs (REGN5713 and REGN5715) given alone or together to reduce eye allergy symptoms caused by birch pollen. About 350 adults with birch pollen allergy will receive the drugs or a placebo and then be exposed to pollen in a controlled setting to m…

This study follows about 500 adults with advanced non-small cell lung cancer who are already prescribed cemiplimab (Libtayo) by their doctor. Researchers want to see how well the drug works and how safe it is in everyday medical practice, not just in controlled trials. The main g…

This study follows about 20 people with chronic kidney disease who received a kidney transplant after being treated with the experimental drug vonsetamig in a previous study. No new drug is given here. Researchers will watch for side effects and how well the transplanted kidney w…

This study is for people with eosinophilic esophagitis (EoE) who are starting Dupixent as part of their normal treatment. Researchers will watch how the medicine is used and how symptoms like trouble swallowing change over time. About 350 participants will fill out questionnaires…

This study follows about 50 people who have already received gene modified T cell therapy in earlier trials. Researchers will check for delayed side effects, how long the modified cells last, and whether the disease gets worse. Participants will have regular check-ups and fill ou…